Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2448人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866677, encodeId=5d9e18666e7d2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：CA-125 KELIM可作为预测维利帕尼疗效的潜在补充预测因子, objectType=article, longId=734316, objectId=c298e34316f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c298e34316f4, replyNumber=0, likeNumber=101, createdTime=2023-01-06, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c298e34316f4, moduleTitle=J Clin Oncol：CA-125 KELIM可作为预测维利帕尼疗效的潜在补充预测因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c298e34316f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866614, encodeId=82781866614df, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD, objectType=article, longId=727795, objectId=19a7e27795a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19a7e27795a3, replyNumber=0, likeNumber=114, createdTime=2023-04-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19a7e27795a3, moduleTitle=J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19a7e27795a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866604, encodeId=3d54186660413, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：Adebrelimab联合化疗一线治疗广泛期小细胞肺癌, objectType=article, longId=727377, objectId=ce1ee2737728, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce1ee2737728, replyNumber=0, likeNumber=75, createdTime=2023-01-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce1ee2737728, moduleTitle=Lancet Oncol：Adebrelimab联合化疗一线治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce1ee2737728)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866640, encodeId=ad1f1866640a4, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Oncologist：单项自评健康测量来确定老年癌症患者相关研究, objectType=article, longId=729479, objectId=6446e2947975, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6446e2947975, replyNumber=0, likeNumber=91, createdTime=2022-10-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6446e2947975, moduleTitle=Oncologist：单项自评健康测量来确定老年癌症患者相关研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6446e2947975)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866605, encodeId=286b186660532, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤, objectType=article, longId=727301, objectId=6669e2730156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6669e2730156, replyNumber=0, likeNumber=76, createdTime=2023-02-02, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6669e2730156, moduleTitle=Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6669e2730156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866630, encodeId=4ff918666302c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：采用KTE-X19治疗复发/难治性套细胞淋巴瘤的3年随访结果, objectType=article, longId=728874, objectId=d52ae288743f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d52ae288743f, replyNumber=0, likeNumber=96, createdTime=2022-12-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d52ae288743f, moduleTitle=J Clin Oncol：采用KTE-X19治疗复发/难治性套细胞淋巴瘤的3年随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d52ae288743f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866590, encodeId=a46c186659064, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：新辅助化疗加用尼达尼布对晚期肌肉浸润性膀胱癌患者预后的影响, objectType=article, longId=724219, objectId=adc4e2421902, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adc4e2421902, replyNumber=0, likeNumber=82, createdTime=2022-10-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adc4e2421902, moduleTitle=Lancet Oncol：新辅助化疗加用尼达尼布对晚期肌肉浸润性膀胱癌患者预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=adc4e2421902)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866687, encodeId=1da4186668ee9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：利妥昔单抗+来那度胺+依鲁替尼治疗新诊断的弥漫性大B细胞淋巴瘤, objectType=article, longId=735739, objectId=d3ece357396e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3ece357396e, replyNumber=0, likeNumber=101, createdTime=2023-07-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3ece357396e, moduleTitle=J Clin Oncol：利妥昔单抗+来那度胺+依鲁替尼治疗新诊断的弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3ece357396e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866672, encodeId=583318666e212, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：戈舍瑞林和他莫西芬辅助治疗绝经前乳腺癌患者的长期益处, objectType=article, longId=734127, objectId=c1d5e3412727, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1d5e3412727, replyNumber=0, likeNumber=109, createdTime=2022-08-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1d5e3412727, moduleTitle=J Clin Oncol：戈舍瑞林和他莫西芬辅助治疗绝经前乳腺癌患者的长期益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1d5e3412727)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866656, encodeId=468d186665690, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Hematol Oncol：诊断为弥漫性大 B 细胞淋巴瘤并接受蒽环类药物治疗的患者心血管事件和死亡率的危险因素, objectType=article, longId=731395, objectId=ba22e3139533, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba22e3139533, replyNumber=0, likeNumber=110, createdTime=2023-03-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba22e3139533, moduleTitle=Hematol Oncol：诊断为弥漫性大 B 细胞淋巴瘤并接受蒽环类药物治疗的患者心血管事件和死亡率的危险因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba22e3139533)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866600, encodeId=0d73186660094, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：为降低结直肠癌风险，多少岁前开始肠镜检查最合适？, objectType=article, longId=726519, objectId=cf33e26519d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf33e26519d9, replyNumber=0, likeNumber=105, createdTime=2022-09-19, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf33e26519d9, moduleTitle=JAMA Oncol：为降低结直肠癌风险，多少岁前开始肠镜检查最合适？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf33e26519d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866683, encodeId=3819186668393, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：cT1-2N1乳腺癌初始化疗后可根据复发风险进行适应性的降级放疗, objectType=article, longId=735466, objectId=adb4e35466ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adb4e35466ed, replyNumber=0, likeNumber=0, createdTime=2023-01-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adb4e35466ed, moduleTitle=Lancet Oncol：cT1-2N1乳腺癌初始化疗后可根据复发风险进行适应性的降级放疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=adb4e35466ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866636, encodeId=5b1518666367f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Oral Oncol：外用氟化物可有效预防成人放射性龋齿, objectType=article, longId=728867, objectId=e1f4e28867e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1f4e28867e2, replyNumber=0, likeNumber=115, createdTime=2023-04-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1f4e28867e2, moduleTitle=Oral Oncol：外用氟化物可有效预防成人放射性龋齿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1f4e28867e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866637, encodeId=1250186663e13, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol：Pimitespib可显著改善TKI难治性晚期胃肠道间质瘤的预后, objectType=article, longId=729557, objectId=269be2955716, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=269be2955716, replyNumber=0, likeNumber=88, createdTime=2022-11-18, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=269be2955716, moduleTitle=Ann Oncol：Pimitespib可显著改善TKI难治性晚期胃肠道间质瘤的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=269be2955716)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866697, encodeId=7fb0186669ead, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Talimogene Laherparepvec联合派姆单抗治疗晚期黑色素瘤, objectType=article, longId=737793, objectId=5560e37793d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5560e37793d5, replyNumber=0, likeNumber=105, createdTime=2023-02-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5560e37793d5, moduleTitle=J Clin Oncol：Talimogene Laherparepvec联合派姆单抗治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5560e37793d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866596, encodeId=30a518665962e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Durvalumab±Oleclumab/Monalizumab巩固治疗3期非小细胞肺癌的疗效和安全性, objectType=article, longId=724969, objectId=492be249698c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=492be249698c, replyNumber=0, likeNumber=103, createdTime=2023-02-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=492be249698c, moduleTitle=J Clin Oncol：Durvalumab±Oleclumab/Monalizumab巩固治疗3期非小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=492be249698c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866698, encodeId=835018666987f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：派姆单抗单药辅助治疗术后高复发风险的肾透明细胞癌, objectType=article, longId=737794, objectId=6a68e377947e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a68e377947e, replyNumber=0, likeNumber=82, createdTime=2023-02-05, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a68e377947e, moduleTitle=Lancet Oncol：派姆单抗单药辅助治疗术后高复发风险的肾透明细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a68e377947e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866608, encodeId=b6211866608b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效, objectType=article, longId=727599, objectId=801de275994a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=801de275994a, replyNumber=0, likeNumber=144, createdTime=2023-04-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=801de275994a, moduleTitle=J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=801de275994a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866617, encodeId=8555186661eda, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：阿美替尼有望成为EGFR突变的NSCLC患者的一线疗法, objectType=article, longId=727709, objectId=f4e9e2770970, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4e9e2770970, replyNumber=0, likeNumber=102, createdTime=2023-02-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4e9e2770970, moduleTitle=J Clin Oncol：阿美替尼有望成为EGFR突变的NSCLC患者的一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4e9e2770970)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866653, encodeId=5c611866653d3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Spartalizumab 联合达拉非尼和曲美替尼治疗黑色素瘤的疗效, objectType=article, longId=729628, objectId=bf1ee296289d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf1ee296289d, replyNumber=0, likeNumber=77, createdTime=2022-07-31, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf1ee296289d, moduleTitle=J Clin Oncol：Spartalizumab 联合达拉非尼和曲美替尼治疗黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf1ee296289d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：CA-125 KELIM可作为预测维利帕尼疗效的潜在补充预测因子

2023-01-06

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD

2023-04-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：Adebrelimab联合化疗一线治疗广泛期小细胞肺癌

2023-01-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Oncologist：单项自评健康测量来确定老年癌症患者相关研究

2022-10-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤

2023-02-02

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：采用KTE-X19治疗复发/难治性套细胞淋巴瘤的3年随访结果

2022-12-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：新辅助化疗加用尼达尼布对晚期肌肉浸润性膀胱癌患者预后的影响

2022-10-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：利妥昔单抗+来那度胺+依鲁替尼治疗新诊断的弥漫性大B细胞淋巴瘤

2023-07-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：戈舍瑞林和他莫西芬辅助治疗绝经前乳腺癌患者的长期益处

2022-08-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Hematol Oncol：诊断为弥漫性大 B 细胞淋巴瘤并接受蒽环类药物治疗的患者心血管事件和死亡率的危险因素

2023-03-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：为降低结直肠癌风险，多少岁前开始肠镜检查最合适？

2022-09-19

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：cT1-2N1乳腺癌初始化疗后可根据复发风险进行适应性的降级放疗

2023-01-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Oral Oncol：外用氟化物可有效预防成人放射性龋齿

2023-04-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol：Pimitespib可显著改善TKI难治性晚期胃肠道间质瘤的预后

2022-11-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Talimogene Laherparepvec联合派姆单抗治疗晚期黑色素瘤

2023-02-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Durvalumab±Oleclumab/Monalizumab巩固治疗3期非小细胞肺癌的疗效和安全性

2023-02-21

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：派姆单抗单药辅助治疗术后高复发风险的肾透明细胞癌

2023-02-05

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效

2023-04-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：阿美替尼有望成为EGFR突变的NSCLC患者的一线疗法

2023-02-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Spartalizumab 联合达拉非尼和曲美替尼治疗黑色素瘤的疗效

2022-07-31

科室
- - 订阅+
  - 更多科室
工具
服务